Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[surf1944]

8:31AM Ligand Pharma presents preclinical data on HepDirect liver-targeting technology platform at 2013 International Liver Congress (EASL); data demonstrated that HepDirect liver targeting of active nucleosides may be an effective method to improve efficacy while reducing systemic side effects in HCV treatment (LGND) 28.04 : Co announced that data from preclinical studies evaluating Ligand's HepDirect liver-targeting technology platform will be featured in a poster presentation at the 48th Annual International Liver Congress hosted by the European Association for the Study of the Liver (EASL) in Amsterdam. The data show highly targeted liver delivery of a clinically active NS5B polymerase inhibitor utilizing the HepDirect technology platform, and demonstrated that HepDirect liver targeting of active nucleosides may be an effective method to improve efficacy while reducing systemic side effects in HCV treatment. The compound using HepDirect technology efficiently targeted the liver with greatly reduced systemic distribution in preclinical models, providing further proof-of-concept of the value and utility of the HepDirect technology platform.